Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community

Contemporary Clinical Trials

Volumn 39, Issue 2, 2014, Pages 256-268

  Di Paola, Angela ^a   Lincoln, Thomas ^c   Skiest, Daniel J ^c   Desabrais, Maureen ^c   Altice, Frederick L ^a,b   Springer, Sandra A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c BAYSTATE MEDICAL CENTER   (United States)

Author keywords

Extended release naltrexone; HIV; Opioid dependence; Prisoners; Randomized controlled trial; Vivitrol

Indexed keywords

BUPRENORPHINE; METHADONE; NALTREXONE; OPIATE; PLACEBO; DELAYED RELEASE FORMULATION; NARCOTIC ANTAGONIST;

ADULT; ARTICLE; CHRONOTHERAPY; CLINICAL PROTOCOL; COMMUNITY LIVING; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG DOSE INCREASE; DRUG PREFERENCE; DRUG RELEASE; EVIDENCE BASED MEDICINE; FEMALE; HEALTH IMPACT ASSESSMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INJECTION SITE REACTION; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; MULTICENTER STUDY; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PATIENT PARTICIPATION; PATIENT PREFERENCE; PATIENT REFERRAL; PRISONER; RANDOMIZED CONTROLLED TRIAL; RELAPSE; TOXIC HEPATITIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; HIGH RISK BEHAVIOR; HIV INFECTIONS; INTERPERSONAL COMMUNICATION; INTRAMUSCULAR DRUG ADMINISTRATION; METHODOLOGY; OPIOID-RELATED DISORDERS; PATIENT COMPLIANCE; TIME;

COMMUNICATION; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PATIENT COMPLIANCE; PRISONERS; RESEARCH DESIGN; RISK-TAKING; TIME FACTORS;

EID: 84908012941     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2014.09.002     Document Type: Article

References (86)

1. Maruschak L., Beavers R. HIV in prisons, 2007-08. Bureau of Justice Statistics Bulletin 2009, U.S. Department of Justice, Office of Justice Programs, Washington, D.C. Bureau of Justice Statistics (Ed.).
2. Spaulding A.C., Seals R.M., Page M.J., Brzozowski A.K., Rhodes W., Hammett T.M. HIV/AIDS among inmates of and releasees from US correctional facilities, 2006: declining share of epidemic but persistent public health opportunity. PLoS One 2009, 4:e7558.
3. Cepeda J.A., Springer S.A. Drug abuse and alcohol dependence among inmates. Encyclopedia of Criminology and Criminal Justice 2014, 1147-1159. Springer.
4. Mumola C.J., Karberg J.C. Drug use and dependence, state and federal prisons, 2004 2006, US Department of Justice, [Document NCJ 213530].
5. Altice FL, Tehrani AS, Qiu J, Herme M, Springer SA Directly Administered Antiretroviral Therapy (DAART) is Superior to Self-Administered Therapy (SAT) Among Released HIV+Prisoners: Results from a Randomized Controlled Trial 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA 2011, p. Abstract K-131.
6. Saber-Tehrani A.S., Springer S.A., Qiu J., Herme M., Wickersham J., Altice F.L. Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community - a potential conduit to improved HIV treatment outcomes. Contemp Clin Trials 2012, 33:436-444.
7. Springer S.A., Qiu J., Saber-Tehrani A.S., Altice F.L. Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners. PLoS One 2012, 7:e38335.
8. Springer S.A., Chen S., Altice F.L. Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment. J Urban Health 2010, 87:592-602.
9. Hammett T.M., Harmon M.P., Rhodes W. The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997. Am J Public Health 2002, 92:1789-1794.
10. Springer S.A., Pesanti E., Hodges J., Macura T., Doros G., Altice F.L. Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. Clin Infect Dis 2004, 38:1754-1760.
11. Springer S.A., Friedland G.H., Doros G., Pesanti E., Altice F.L. Antiretroviral treatment regimen outcomes among HIV-infected prisoners. HIV Clin Trials 2007, 8:205-212.
12. Meyer J.P., Cepeda J., Wu J., Trestman R.L., Altice F.L., Springer S.A. Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gate. JAMA Intern Med 2014, 174:721-729.
13. Stephenson B.L., Wohl D.A., Golin C.E., Tien H.C., Stewart P., Kaplan A.H. Effect of release from prison and re-incarceration on the viral loads of HIV-infected individuals. Public Health Rep 2005, 120:84-88.
14. Althoff A.L., Zelenev A., Meyer J.P., Fu J., Brown S.E., Vagenas P., et al. Correlates of retention in HIV care after release from jail: results from a multi-site study. AIDS Behav 2013, 17(Suppl 2):S156-S170.
15. Krishnan A., Wickersham J.A., Chitsaz E., Springer S.A., Jordan A.O., Zaller N., et al. Post-release substance abuse outcomes among HIV-infected jail detainees: results from a multisite study. AIDS Behav 2013, 17:S171-S180.
16. Krishnan A., Ferro E.G., Weikum D., Vagenas P., Lama J.R., Gonzales P., et al. Communication technology use and mHealth acceptance among HIV-infected men who have sex with men in Peru: implications for HIV prevention and treatment. AIDS Care 2014, [in press]. 10.1080/09540121.2014.963014.
17. Baillargeon J., Giordano T.P., Rich J.D., Wu Z.H., Wells K., Pollock B.H., et al. Accessing antiretroviral therapy following release from prison. JAMA 2009, 301:848-857.
18. Meyer J.P., Althoff A.L., Altice F.L. Optimizing care for HIV-infected people who use drugs: evidence-based approaches to overcoming healthcare disparities. Clin Infect Dis 2013, 57:1309-1317.
19. Levasseur L., Marzo J.N., Ross N., Blatier C. Frequency of re-incarcerations in the same detention center: role of substitution therapy. A preliminary retrospective analysis. Ann Med Interne 2002, 153. [1S14-9].
20. Fu J.J., Herme M., Wickersham J.A., Zelenev A., Althoff A., Zaller N.D., et al. Understanding the revolving door: individual and structural-level predictors of recidivism among individuals with HIV leaving jail. AIDS Behav 2013, 17(Suppl 2):S145-S155.
21. Binswanger I.A., Blatchford P.J., Lindsay R.G., Stern M.F. Risk factors for all-cause, overdose and early deaths after release from prison in Washington state. Drug Alcohol Depend 2011, 117:1-6.
22. Binswanger I.A., Stern M.F., Deyo R.A., Heagerty P.J., Cheadle A., Elmore J.G., et al. Release from prison-a high risk of death for former inmates. N Engl J Med 2007, 356:157-165.
23. Harding-Pink D. Mortality following release from prison. Med Sci Law 1990, 30:12-16.
24. Harding-Pink D., Fryc O. Risk of death after release from prison: a duty to warn. BMJ 1988, 297:596.
25. Merrall E.L., Kariminia A., Binswanger I.A., Hobbs M.S., Farrell M., Marsden J., et al. Meta-analysis of drug-related deaths soon after release from prison. Addiction 2010, 105:1545-1554.
26. Binswanger I.A., Blatchford P.J., Mueller S.R., Stern M.F. Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann Intern Med 2013, 159:592-600.
27. Krinsky C.S., Lathrop S.L., Brown P., Nolte K.B. Drugs, detention, and death: a study of the mortality of recently released prisoners. Am J Forensic Med Pathol 2009, 30:6-9.
28. Thompson M.A., Mugavero M.J., Amico K.R., Cargill V.A., Chang L.W., Gross R., et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med 2012, 156:817-833.
29. Smith-Rohrberg D., Bruce R.D., Altice F.L. Review of corrections-based therapy for opiate-dependent patients: implications for buprenorphine treatment among correctional populations. J Drug Issues 2004, 34:451-480.
30. Springer S. Commentary on Larney (2010): a call to action-opioid substitution therapy as a conduit to routine care and primary prevention of HIV transmission among opioid-dependent prisoners. Addiction 2010, 105:224-225.
31. Kinlock T.W., Gordon M.S., Schwartz R.P., Fitzgerald T.T., O'Grady K.E. A randomized clinical trial of methadone maintenance for prisoners: results at 12months postrelease. J Subst Abuse Treat 2009, 37:277-285.
32. Coviello D.M., Cornish J.W., Lynch K.G., Boney T.Y., Clark C.A., Lee J.D., et al. A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers. Subst Abus 2011, 33:48-59.
33. Friedmann P.D., Taxman F.S., Henderson C.E. Evidence-based treatment practices for drug-involved adults in the criminal justice system. J Subst Abuse Treat 2007, 32:267-277.
34. Magura S., Lee J.D., Hershberger J., Joseph H., Marsch L., Shropshire C., et al. Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial. Drug Alcohol Depend 2009, 99:222-230.
35. Center on Budget and Policy Priorities. The Number of Uninsured Americans is at an All-Time High. Washington, D.C. 2006 Accessed from on March 1, 2008. http://www.cbpp.org/8-29-06health.htm.
36. Chandler R.K., Fletcher B.W., Volkow N.D. Treating drug abuse and addiction in the criminal justice system: improving public health and safety. JAMA 2009, 301:183-190.
37. Fletcher B., Lehman W., Wexler H., Melnick G., Taxman F., Young D. Measuring collaboration and integration activities in criminal justice and substance abuse treatment agencies. Drug Alcohol Depend 2009, 103(Suppl 1):S54-S64.
38. Nunn A., Zaller N., Dickman S., Trimbur C., Nijhawan A., Rich J.D. Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. Drug Alcohol Depend 2009, 105:83-88.
39. Gordon M.S., Kinlock T.W., Schwartz R.P., Fitzgerald T.T., O'Grady K.E., Vocci F.J. A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry. Drug Alcohol Depend 2014, 142:33-40.
40. National Institute of Drug Abuse Seek, test, treat and retain Retrieved January 20, 2014. http://www.drugabuse.gov/researchers/research-resources/data-harmonization-projects/seek-test-treat-retain.
41. Kinlock T.W., Gordon M.S., Schwartz R.P., O'Grady K.E. A study of methadone maintenance for male prisoners: 3-month postrelease outcomes. Crim Justice Behav 2008, 35:34-47.
42. Springer S.A., Spaulding A.C., Meyer J.P., Altice F.L. Public health implications for adequate transitional care for HIV-infected prisoners: five essential components. Clin Infect Dis 2011, 53:469-479.
43. Wickersham J.A., Azar M.M., Cannon C.M., Altice F.L., Springer S.A. Development of a brief measure of opioid dependence: the rapid opioid dependence screen (RODS). J Correct Health Care 2014, 21(1).
44. Levine J., Schooler N.R. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 1986, 22:343-381.
45. International Harm Reduction Development Program (IHRD) of the Open Society Institute (OSI) Barriers to access: medication-assisted treatment and injection-driven HIV epidemics 2008, 1-5. Open Society Institute, New York, NY, [http://wwwsorosorg/initiatives/health/focus/ihrd/articles_publications/publications/barriers_20080215/barriersfootnotes040808pdf]. Open Society Institute (OSI) (Ed.).
46. Scott N.W., McPherson G.C., Ramsay C.R., Campbell M.K. The method of minimization for allocation to clinical trials. A review. Control Clin Trials 2002, 23:662-674.
47. Kang M., Ragan B.G., Park J.H. Issues in outcomes research: an overview of randomization techniques for clinical trials. J Athl Train 2008, 43:215-221.
48. Tideman R.L., Chen M.Y., Pitts M.K., Ginige S., Slaney M., Fairley C.K. A randomised controlled trial comparing computer-assisted with face-to-face sexual history taking in a clinical setting. Sex Transm Infect 2007, 83:52-56.
49. Caldwell D.H., Jan G. Computerized assessment facilitates disclosure of sensitive HIV risk behaviors among African Americans entering substance abuse treatment. Am J Drug Alcohol Abuse 2012, 38:365-369.
50. Azbel L., Wickersham J.A., Grishaev Y., Dvoryak S., Altice F.L. Burden of infectious diseases, substance use disorders, and mental illness among Ukrainian prisoners transitioning to the community. PLoS One 2013, 8:e59643.
51. Amico K.R., Fisher W., Cornman D., Shuper P., Redding C., Konkle-Parker D., et al. Visual analog scale of ART adherence: association with 3-day self-report and adherence barriers. J Acquir Immune Defic Syndr Hum Retrovirol 2006, 42:455-459.
52. Pettinati H., Weiss R., Miller W.R., Donovan D., Ernst D., BJ R. Medical management treatment providing pharmacotherapy as part of the treatment for alcohol dependence 2004, DHHS, Bethesda, MD. NIAAA (Ed.).
53. Tompkins D.A., Bigelow G.E., Harrison J.A., Johnson R.E., Fudala P.J., Strain E.C. Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument. Drug Alcohol Depend 2009, 105:154-159.
54. National Institute on Alcohol Abuse and Alcoholism Helping patients who drink too much: a clinician's guide 2005, NIAAA. 2005 ed. NIAAA (Ed.).
55. Anton R.F., O'Malley S.S., Ciraulo D.A., Cisler R.A., Couper D., Donovan D.M., et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006, 295:2003-2017.
56. Copenhaver M.M., Bruce R.D., Altice F.L. Behavioral counseling content for optimizing the use of buprenorphine for treatment of opioid dependence in community-based settings: a review of the empirical evidence. Am J Drug Alcohol Abuse 2007, 33:643-654.
57. Copenhaver M., Avants S.K., Warburton L.A., Margolin A. Intervening effectively with drug abusers infected with HIV: taking into account the potential for cognitive impairment. J Psychoactive Drugs 2003, 35:209-218.
58. Miller W.R., Arciniega L.T. Combined behavioral intervention manual: a clinical research guide for therapists treating people with alcohol abuse and dependence 2004, US Department of Health and Human Services, National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism.
59. Vivitol (R) 2013, [package instert], Alkermes, Inc, Waltham, MA.
60. Springer S.A., Altice F.L., Herme M., Di Paola A. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community. Contemp Clin Trials 2013, 37:209-218.
61. Copersino M.L., Meade C.S., Bigelow G.E., Brooner R.K. Measurement of self-reported HIV risk behaviors in injection drug users: comparison of standard versus timeline follow-back administration procedures. J Subst Abuse Treat 2010, 38:60-65.
62. Maruschak L. HIV in prisons, 2001-2010 2012, Bureau of Jstive Statistics.
63. Rich J.D., Boutwell A.E., Shield D.C., Key R.G., McKenzie M., Clarke J.G., et al. Attitudes and practices regarding the use of methadone in US state and federal prisons. J Urban Health 2005, 82:411-419.
64. Krupitsky E.M., Blokhina E.A. Long-acting depot formulations of naltrexone for heroin dependence: a review. Curr Opin Psychiatry 2010, 23:210-214. 10.1097/YCO.0b013e3283386578.
65. Gastfriend D.R. Intramuscular extended-release naltrexone: current evidence. Ann N Y Acad Sci 2011, 1216:144-166.
66. Wickersham J.A., Marcus R., Kamarulzaman A., Zahari M.M., Altice F.L. Implementing methadone maintenance treatment in prisons in Malaysia. Bull World Health Organ 2013, 91:124-129.
67. Wickersham J.A., Zahari M.M., Azar M.M., Kamarulzaman A., Altice F.L. Methadone dose at the time of release from prison significantly influences retention in treatment: implications from a pilot study of HIV-infected prisoners transitioning to the community in Malaysia. Drug Alcohol Depend 2013, 132:378-382.
68. Mitchell M.C., Memisoglu A., Silverman B.L. Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection. J Stud Alcohol Drugs 2012, 73:991-997.
69. Vagenas P., Di Paola A., Herme M., Lincoln T., Skiest D.J., Altice F.L., et al. An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone. J Subst Abuse Treat 2014, 47:35-40.
70. Krupitsky E., Nunes E.V., Ling W., Illeperuma A., Gastfriend D.R., Silverman B.L. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 2011, 377:1506-1513.
71. Delate T., Coons S.J. The discriminative ability of the 12-item short form health survey (SF-12) in a sample of persons infected with HIV. Clin Ther 2000, 22:1112-1120.
72. Amorim P., Lecrubier Y., Weiller E., Hergueta T., Sheehan D. DSM-IH-R Psychotic Disorders: procedural validity of the Mini International Neuropsychiatric Interview (MINI). Concordance and causes for discordance with the CIDI. Eur Psychiatry 1998, 13:26-34.
73. Sheehan D., Lecrubier Y., Harnett-Sheehan K., Janavs J., Weiller E., Bonors L., et al. Reliability and validity of the MINI International Neuropsychiatric Interview (M.I.N.I.): according to the SCID-P. Eur Psychiatry 1997, 12:232-241.
74. Lecrubier Y., Sheehan D.V., Weiller E., Amorim P., Bonora I., Sheehan K.H., et al. The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry 1997, 12:224-231.
75. Wang J., Kelly B.C., Booth B.M., Falck R.S., Leukefeld C., Carlson R.G. Examining factorial structure and measurement invariance of the Brief Symptom Inventory (BSI)-18 among drug users. Addict Behav 2010, 35:23-29.
76. Derogatis L.R. BSI 18, Brief Symptom Inventory 18: administration, scoring and procedures manual 2001, NCS Pearson, Incorporated.
77. Derogatis L.R. Brief symptom inventory 18 (BSI-18) manual 2001, NCS Assessments, Minnetonka, MN.
78. McLellan A.T., Kushner H., Metzger D., Peters R., Smith I., Grissom G., et al. The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat 1992, 9:199-213.
79. Rosen C., Henson B., Finney J., Moos R. Consistency of self-administered and interview-based Addiction Severity Index composite scores. Addiction 2000, 95:419-425.
80. Cacciola J.S., Alterman A.I., McLellan A.T., Lin Y.-T., Lynch K.G. Initial evidence for the reliability and validity of a "Lite" version of the Addiction Severity Index. Drug Alcohol Depend 2007, 87:297-302.
81. Barbor E.A. The AUDIT, guidelines for use in primary care 2001, World health organization.
82. Saunders J.B., Aasland O.G., Babor T.F., de la Fuente J.R., Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II. Addiction 1993, 88:791-804.
83. Sobell L.C., Toneatto T., Sobell M.B., Leo G.I., Johnson L. Alcohol abusers' perceptions of the accuracy of their self-reports of drinking: implications for treatment. Addict Behav 1992, 17:507-511.
84. Sobell L.C., Sobell M.B. Alcohol Timeline Followback (TLFB). Handbook of Psychiatric Measures 2000, 477-479. American Psychiatric Association, Washington, DC.
85. Fisher J.D., Fisher W.A., Cornman D.H., Amico R.K., Bryan A., Friedland G.H. Clinician-delivered intervention during routine clinical care reduces unprotected sexual behavior among HIV-infected patients. J Acquir Immune Defic Syndr 2006, 41:44-52.
86. Johnson B.A., Ait-Daoud N., Roache J.D. The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field. J Stud Alcohol Suppl 2005, 157-167. [discussion 40].